Parthenolide: From plant shoots to cancer roots

Drug Discovery Today

Volumn 18, Issue 17-18, 2013, Pages 894-905

  Ghantous, Akram ^a   Sinjab, Ansam ^b   Herceg, Zdenko ^a   Darwiche, Nadine ^c  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYNONENAL; ANTINEOPLASTIC AGENT; CARBOXYPEPTIDASE; CELASTROL; DACARBAZINE; DIMETHYLAMINO PARTHENOLIDE; DNA METHYLTRANSFERASE 1; I KAPPA B; LAPATINIB; METFORMIN; PACLITAXEL; PARTHENOLIDE; SALINOMYCIN; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; CANCER STEM CELL; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; OXIDATION REDUCTION POTENTIAL; PLANT ROOT; REVIEW; SHOOT; TANACETUM PARTHENIUM;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; HUMANS; MOLECULAR STRUCTURE; NEOPLASTIC STEM CELLS; PHYTOTHERAPY; PLANT SHOOTS; PLANTS, MEDICINAL; SESQUITERPENES; STRUCTURE-ACTIVITY RELATIONSHIP; TANACETUM PARTHENIUM;

EID: 84883233659     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2013.05.005     Document Type: Review

References (83)

1. D.W. Knight Feverfew: chemistry and biological activity Nat. Prod. Rep. 12 1995 271 276
2. C. Hobbs Tanacetum parthenium HerbalGram 20 1989 267 270
3. A. Pareek Feverfew (Tanacetum parthenium L.): a systematic review Pharmacogn. Rev. 5 2011 103 110
4. F. Bohlmann, and C. Zdero Sesquiterpene lactones and other constituents from Tanacetum parthenium Phytochemistry 21 1982 2543 2549
5. A. Stojakowska, and W. Kisiel Production of parthenolide in organ cultures of feverfew Plant Cell Tissue Organ Cult. 47 1997 159 162
6. D.V.C. Awang Parthenolide content of feverfew (Tanacetum parthenium) assessed by HPLC and IH-NMR spectroscopy J. Nat. Prod. 54 1991 1516 1521
7. R.M. Wiedhopf Tumor inhibitory agent from Magnolia grandiflora (Magnoliaceae). I. Parthenolide J. Pharm. Sci. 62 1973 345
8. P.M. Bork Sesquiterpene lactone containing Mexican Indian medicinal plants and pure sesquiterpene lactones as potent inhibitors of transcription factor NF-kappaB FEBS Lett. 402 1997 85 90
9. A.J. Garcia-Pineres Cysteine 38 in p65/NF-kappaB plays a crucial role in DNA binding inhibition by sesquiterpene lactones J. Biol. Chem. 276 2001 39713 39720
10. S.P. Hehner The antiinflammatory sesquiterpene lactone parthenolide inhibits NF-kappa B by targeting the I kappa B kinase complex J. Immunol. 163 1999 5617 5623
11. B.H. Kwok The anti-inflammatory natural product parthenolide from the medicinal herb Feverfew directly binds to and inhibits IkappaB kinase Chem. Biol. 8 2001 759 766
12. S. Zhang Anti-cancer potential of sesquiterpene lactones: bioactivity and molecular mechanisms Curr. Med. Chem. Anticancer Agents 5 2005 239 249
13. H. Nakshatri, and C.J. Sweeney Use of Parthenolide to Inhibit Cancer 2005 Indiana University Research and Technology Corporation Patent US 6890946 B2
14. Y.N. Gopal Parthenolide specifically depletes histone deacetylase 1 protein and induces cell death through ataxia telangiectasia mutated Chem. Biol. 14 2007 813 823
15. Z. Liu Modulation of DNA methylation by a sesquiterpene lactone parthenolide J. Pharmacol. Exp. Ther. 329 2009 505 514
16. A. Ghantous Inhibition of tumor promotion by parthenolide: epigenetic modulation of p21 Cancer Prev. Res. 5 2012 1298 1309
17. R. Schneider-Stock Epigenetic mechanisms of plant-derived anticancer drugs Front. Biosci. 17 2012 129 173
18. V.B. Mathema Parthenolide, a sesquiterpene lactone, expresses multiple anti-cancer and anti-inflammatory activities Inflammation 35 2012 560 565
19. M.R. Kreuger Sesquiterpene lactones as drugs with multiple targets in cancer treatment: focus on parthenolide Anticancer Drugs 23 2012 883 896
20. B. Pajak Molecular basis of parthenolide-dependent proapoptotic activity in cancer cells Folia Histochem. Cytobiol. 46 2008 129 135
21. M.L. Guzman An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells Blood 110 2007 4427 4435
22. A. Ghantous What made sesquiterpene lactones reach cancer clinical trials? Drug Discov. Today 15 2010 668 678
23. K. Lesiak Parthenolide, a sesquiterpene lactone from the medical herb feverfew, shows anticancer activity against human melanoma cells in vitro Melanoma Res. 20 2010 21 34
24. S. Pei, and C.T. Jordan How close are we to targeting the leukemia stem cell? Best Pract Res. Clin. Haematol. 25 2012 415 418
25. B. Siedle Quantitative structure-activity relationship of sesquiterpene lactones as inhibitors of the transcription factor NF-kappaB J. Med. Chem. 47 2004 6042 6054
26. M. Dell'Agli Inhibition of NF-kB and metalloproteinase-9 expression and secretion by parthenolide derivatives Bioorg. Med. Chem. Lett. 19 2009 1858 1860
27. S. Nasim Melampomagnolide B: a new antileukemic sesquiterpene Bioorg. Med. Chem. 19 2011 1515 1519
28. I. Merfort Perspectives on sesquiterpene lactones in inflammation and cancer Curr. Drug Targets 12 2011 1560 1573
29. J. Skalska Modulation of cell surface protein free thiols: a potential novel mechanism of action of the sesquiterpene lactone parthenolide PLoS ONE 4 2009 e8115
30. X. Fonrose Parthenolide inhibits tubulin carboxypeptidase activity Cancer Res. 67 2007 3371 3378
31. M.L. Guzman The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells Blood 105 2005 4163 4169
32. S. Neelakantan Aminoparthenolides as novel anti-leukemic agents: discovery of the NF-kappaB inhibitor, DMAPT (LC-1) Bioorg. Med. Chem. Lett. 19 2009 4346 4349
33. Crooks, P.A. et al. (2012) Use of parthenolide derivatives as antileukemic and cytotoxic agents. University of Kentucky, Patent number US 7312242
34. K. Peese New agents for the treatment of leukemia: discovery of DMAPT (LC-1) Drug Discov. Today 15 2010 253 324
35. S. Nasim, and P.A. Crooks Antileukemic activity of aminoparthenolide analogs Bioorg. Med. Chem. Lett. 18 2008 3870 3873
36. E.J. Gunn The natural products parthenolide and andrographolide exhibit anti-cancer stem cell activity in multiple myeloma Leuk. Lymphoma 52 2011 1085 1097
37. C.M. Salisbury, and B.F. Cravatt Optimization of activity-based probes for proteomic profiling of histone deacetylase complexes J. Am. Chem. Soc. 130 2008 2184 2194
38. B.T. Kawasaki Effects of the sesquiterpene lactone parthenolide on prostate tumor-initiating cells: an integrated molecular profiling approach Prostate 69 2009 827 837
39. D. Cheng Analytical method development and pharmacokinetics studies with parthenolide (NSC 157035) and a water-soluble analog (NSC 734325) AACR Meeting Abstracts (Vol. 1) 2005 AACR pp. 988
40. P. Valent Cancer stem cell definitions and terminology: the devil is in the details Nat. Rev. Cancer 12 2012 767 775
41. M.L. Guzman, and C.T. Jordan Feverfew: weeding out the root of leukaemia Expert Opin. Biol. Ther. 5 2005 1147 1152
42. R. Zobalova Drugs that kill cancer stem-like cells S. Shostak, Cancer Stem Cells Theories and Practice 2011 InTech 361 378
43. J. Zhou, and Y. Zhang Cancer stem cells: models, mechanisms and implications for improved treatment Cell Cycle 7 2008 1360 1370
44. J. Zhou NF-kappaB pathway inhibitors preferentially inhibit breast cancer stem-like cells Breast Cancer Res. Treat. 111 2008 419 427
45. A. Dey Double-edged swords as cancer therapeutics: simultaneously targeting p53 and NF-kappaB pathways Nat. Rev. Drug Discov. 7 2008 1031 1040
46. O. Dreesen, and A.H. Brivanlou Signaling pathways in cancer and embryonic stem cells Stem Cell Rev. 3 2007 7 17
47. D.C. Hassane Chemical genomic screening reveals synergism between parthenolide and inhibitors of the PI-3 kinase and mTOR pathways Blood 116 2010 5983 5990
48. Y.A. Ivanenkov Small molecule inhibitors of NF-kB and JAK/STAT signal transduction pathways as promising anti-inflammatory therapeutics Mini Rev. Med. Chem. 11 2011 55 78
49. X. Shi Reactive oxygen species in cancer stem cells Antioxid. Redox Signal. 16 2012 1215 1228
50. Y.R. Kim Myeloperoxidase expression as a potential determinant of parthenolide-induced apoptosis in leukemia bulk and leukemia stem cells J. Pharmacol. Exp. Ther. 335 2010 389 400
51. M. Czyz Parthenolide reduces the frequency of ABCB5-positive cells and clonogenic capacity of melanoma cells from anchorage independent melanospheres Cancer Biol. Ther. 14 2013 135 145
52. T. Schatton Identification of cells initiating human melanomas Nature 451 2008 345 349
53. D.C. Hassane Discovery of agents that eradicate leukemia stem cells using an in silico screen of public gene expression data Blood 111 2008 5654 5662
54. M. Widschwendter Epigenetic stem cell signature in cancer Nat. Genet. 39 2007 157 158
55. Y. Liu A potential target associated with both cancer and cancer stem cells: a combination therapy for eradication of breast cancer using vinorelbine stealthy liposomes plus parthenolide stealthy liposomes J. Control Release 129 2008 18 25
56. Y.K. Won Chemopreventive activity of parthenolide against UVB-induced skin cancer and its mechanisms Carcinogenesis 25 2004 1449 1458
57. D. Zuch Targeting radioresistant osteosarcoma cells with parthenolide J. Cell. Biochem. 113 2012 1282 1291
58. C. Wang Combined effects of FLT3 and NF-kappaB selective inhibitors on acute myeloid leukemia in vivo J. Biochem. Mol. Toxicol. 26 2012 35 43
59. P.A. Spagnuolo Inhibition of intracellular dipeptidyl peptidases 8 and 9 enhances parthenolide's anti-leukemic activity Leukemia 2013 10.1038/leu.2013.9
60. P. Diamanti Parthenolide eliminates leukemia-initiating cell populations and improves survival in xenografts of childhood acute lymphoblastic leukemia Blood 121 2013 1384 1393
61. R. Shanmugam A water soluble parthenolide analog suppresses in vivo tumor growth of two tobacco-associated cancers, lung and bladder cancer, by targeting NF-kappaB and generating reactive oxygen species Int. J. Cancer 128 2011 2481 2494
62. Y. Kishida Parthenolide, a natural inhibitor of Nuclear Factor-kappaB, inhibits lung colonization of murine osteosarcoma cells Clin. Cancer Res. 13 2007 59 67
63. A.I. Idris Pharmacologic inhibitors of IkappaB kinase suppress growth and migration of mammary carcinosarcoma cells in vitro and prevent osteolytic bone metastasis in vivo Mol. Cancer Ther. 8 2009 2339 2347
64. H. Nakabayashi, and K. Shimizu Involvement of Akt/NF-kappaB pathway in antitumor effects of parthenolide on glioblastoma cells in vitro and in vivo BMC Cancer 12 2012 453
65. C.J. Sweeney The sesquiterpene lactone parthenolide in combination with docetaxel reduces metastasis and improves survival in a xenograft model of breast cancer Mol. Cancer Ther. 4 2005 1004 1012
66. S.L. Kim Parthenolide suppresses tumor growth in a xenograft model of colorectal cancer cells by inducing mitochondrial dysfunction and apoptosis Int. J. Oncol. 2012 10.3892/ijo.2012.1587
67. S.L. Kim Synergistic antitumor effect of 5-fluorouracil in combination with parthenolide in human colorectal cancer Cancer Lett. 41 2013 1547 1553
68. D. Oka Sesquiterpene lactone parthenolide suppresses tumor growth in a xenograft model of renal cell carcinoma by inhibiting the activation of NF-kappaB Int. J. Cancer 120 2007 2576 2581
69. I.H. Kim Parthenolide-induced apoptosis of hepatic stellate cells and anti-fibrotic effects in an in vivo rat model Exp. Mol. Med. 44 2012 448 456
70. R.C. Vegeler Effect of celecoxib and novel agent LC-1 in a hamster model of lung cancer J. Surg. Res. 143 2007 169 176
71. D. Zhang Nuclear factor-kappaB inhibition by parthenolide potentiates the efficacy of Taxol in non-small cell lung cancer in vitro and in vivo Mol. Cancer Res. 7 2009 1139 1149
72. Z.W. Gao Paclitaxel efficacy is increased by parthenolide via nuclear factor-kappaB pathways in in vitro and in vivo human non-small cell lung cancer models Curr. Cancer Drug Targets 10 2010 705 715
73. R. Uchibori NF-kappaB activity regulates mesenchymal stem cell accumulation at tumor sites Cancer Res. 73 2013 364 372
74. M.T. Yip-Schneider Suppression of pancreatic tumor growth by combination chemotherapy with sulindac and LC-1 is associated with cyclin D1 inhibition in vivo Mol. Cancer Ther. 6 2007 1736 1744
75. M.T. Yip-Schneider Effect of celecoxib and the novel anti-cancer agent, dimethylamino-parthenolide, in a developmental model of pancreatic cancer Pancreas 37 2008 e45 e53
76. W. Wang A novel combination therapy with arsenic trioxide and parthenolide against pancreatic cancer cells Pancreas 38 2009 e114 e123
77. T. Taguchi Suppressive effects of dehydroepiandrosterone and the nuclear factor-kappaB inhibitor parthenolide on corticotroph tumor cell growth and function in vitro and in vivo J. Endocrinol. 188 2006 321 331
78. R. Shanmugam Restoring chemotherapy and hormone therapy sensitivity by parthenolide in a xenograft hormone refractory prostate cancer model Prostate 66 2006 1498 1511
79. R. Shanmugam A water-soluble parthenolide analogue suppresses in vivo prostate cancer growth by targeting NFkappaB and generating reactive oxygen species Prostate 70 2010 1074 1086
80. K. Tanaka Prevention of the ultraviolet B-mediated skin photoaging by a nuclear factor kappaB inhibitor, parthenolide J. Pharmacol. Exp. Ther. 315 2005 624 630
81. I. Sohma Parthenolide, an NF-kappaB inhibitor, suppresses tumor growth and enhances response to chemotherapy in gastric cancer Cancer Genomics Proteomics 8 2011 39 47
82. J. Yi Effect of parthenolide on leukemia K562 cells and its leukemia stem cells Zhongguo Zhong Yao Za Zhi 35 2010 219 222
83. R. Birnie Gene expression profiling of human prostate cancer stem cells reveals a pro-inflammatory phenotype and the importance of extracellular matrix interactions Genome Biol. 9 2008 R83